<?xml version="1.0" encoding="UTF-8"?>
<ref id="B5">
 <label>5.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Feagan</surname>
    <given-names>BG</given-names>
   </name>
   <name>
    <surname>Rutgeerts</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Sands</surname>
    <given-names>BE</given-names>
   </name>
   <name>
    <surname>Hanauer</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Colombel</surname>
    <given-names>JF</given-names>
   </name>
   <name>
    <surname>Sandborn</surname>
    <given-names>WJ</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Vedolizumab as induction and maintenance therapy for ulcerative colitis</article-title>. 
  <source>N Engl J Med.</source> (
  <year>2013</year>) 
  <volume>369</volume>:
  <fpage>699</fpage>â€“
  <lpage>710</lpage>. 
  <pub-id pub-id-type="doi">10.1056/NEJMoa1215734</pub-id>
  <pub-id pub-id-type="pmid">23964932</pub-id>
 </mixed-citation>
</ref>
